High Q Uses Quantum EPR Sensing to Watch Proteins Move for Drug Research

An Ontario startup, High Q Technologies, is using quantum sensing to study how proteins move, which it says could help speed up drug discovery for Alzheimer’s and other neurodegenerative diseases. Its platform, called Fathom, is built on electron paramagnetic resonance spectroscopy, a technique that reads the magnetic signature of unpaired electrons to infer a protein’s structure and motion. The details here come from a report by the medical news site MedPath.

How quantum-enhanced EPR tracks protein motion

Proteins bend and shift as they work, and many drugs act by changing that motion, so seeing the full range of movement matters. High Q says Fathom, by adding quantum sensors, can capture several protein configurations at once rather than just the most common one. That aims to complement methods like X-ray crystallography, which tend to show stable snapshots. The company, founded in 2013 out of the University of Waterloo, also pitches the tool as a screening step to weed out samples before more expensive analysis.

Why the Alzheimer’s claims need perspective

The Alzheimer’s framing is a goal, not a result. Fathom measures protein dynamics; it has not produced a drug, and the claims about shorter timelines and lower costs are the company’s own. That caution is important here in particular, because neurodegenerative diseases are where promising early results have repeatedly failed in late-stage trials, a point the source itself makes. “Quantum-enabled” is also worth reading plainly: this is an EPR platform using quantum sensing as one component, not a quantum computer.

The news peg is a partnership with Creative Biostructure, a contract research organization serving more than 3,000 customers in 60 countries, to widen access. High Q’s work has had backing from Canadian government programs, Quantum Valley Investments, and Waterloo’s quantum accelerator.